Cardiac safety and antitumoral activity of a new nitric oxide derivative of pegylated epirubicin in mice

Anti-Cancer Drugs

Volumn 18, Issue 9, 2007, Pages 1081-1091

  Santucci, Luca ^a,c   Mencarelli, Andrea ^a   Renga, Barbara ^a   Ceccobelli, Daniela ^a   Pasut, Gianfranco ^b   Veronese, Francesco M ^b   Distrutti, Eleonora ^a   Fiorucci, Stefano ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

Author keywords

Anthracycline cardiomyopathy; Apoptosis; Caco 2; SKOV 2; Xenograft

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BP 747; CREATINE KINASE; EPIRUBICIN; NITRIC OXIDE; PEGYLATED EPIRUBICIN; TROPONIN; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASCITES; CANCER SURVIVAL; CARDIOMYOPATHY; CARDIOTOXICITY; CELL STRAIN CACO 2; CHEMICAL ANALYSIS; COLON ADENOCARCINOMA; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DEATH; DRUG SAFETY; FEMALE; HEART WEIGHT; HEPATOMEGALY; HUMAN; HUMAN CELL; LETHARGY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIDE EFFECT; TUMOR VOLUME; WEIGHT REDUCTION;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CARDIOMYOPATHIES; CASPASES; CELL LINE, TUMOR; CREATINE KINASE; EPIRUBICIN; HEART; IN SITU NICK-END LABELING; MICE; MICE, INBRED BALB C; MYOCARDIUM; MYOCYTES, CARDIAC; NEOPLASM TRANSPLANTATION; NEOPLASMS; POLYETHYLENE GLYCOLS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TROPONIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 34548074654     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3281db8322     Document Type: Article

References (47)

1. Poole CJ, Earl HM, Hiller L, Dunn JA, Bathers S, Grieve RJ, et al. Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer. N Engl J Med 2006; 355:1851-1862.
2. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006; 354:166-178.
3. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 1998; 339:900-905.
4. Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol 2002; 13:699-709.
5. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003; 97:2869-2879.
6. Arola OJ, Saraste A, Pulkki K, Kallajoki M, Parvinen M, Voipio-Pulkki LM. Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis. Cancer Res 2000; 60:1789-1792.
7. Kelso EJ, Geraghty RF, McDermott BJ, Cameron CH, Nicholls DP, Silke B. Characterization of a cellular model of cardiomyopathy, in the rabbit, produced by chronic administration of the anthracycline epirubicin. J Mol Cell Cardiol 1997; 29:3385-3397.
8. Sacco G, Giampietro R, Salvatorelli E, Menna P, Bertani N, Graiani G, et al. Chronic cardiotoxicity of anticancer anthracyclines in the rat: role of secondary metabolites and reduced toxicity by a novel anthracycline with impaired metabolite formation and reactivity. Br J Pharmacol 2003; 139:641-651.
9. Childs AC, Phaneuf SL, Dirks AJ, Phillips T, Leeuwenburgh C. Doxorubicin treatment in vivo causes cytochrome c release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and Bcl-2:Bax ratio. Cancer Res 2002; 62:4592-4598.
10. Wallace KB. Doxorubicin-induced cardiac mitochondrionopathy. Pharmacol Toxicol 2003; 93:105-115.
11. Jeyaseelan R, Poizat C, Baker RK, Abdishoo S, Isterabadi LB, Lyons GE, et al. A novel cardiac-restricted target for doxorubicin. CARP, a nuclear modulator of gene expression in cardiac progenitor cells and cardiomyocytes. J Biol Chem 1997; 272:22800-22808.
12. Aihara Y, Kurabayashi M, Arai M, Kedes L, Nagai R. Molecular cloning of rabbit CARP cDNA and its regulated expression in adriamycin-cardiomyopathy. Biochim Biophys Acta 1999; 1447:318-324.
13. Olson RD, Gambliel HA, Vestal RE, Shadle SE, Charlier HA Jr, Cusack BJ. Doxorubicin cardiac dysfunction: effects on calcium regulatory proteins, sarcoplasmic reticulum, and triiodothyronine. Cardiovasc Toxicol 2005; 5:269-283.
14. van Dalen EC, Michiels EMC, Caron HN, Kremer LCM. Different anthracycline derivatives for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev 2006; 18:CD005006.
15. Markman M, Gordon AN, McGuire WP, Muggia FM. Liposomal anthracycline treatment for ovarian cancer. Semin Oncol 2004; 31:91-105.
16. Hofheinz RD, Gnad-Vogt SU, Beyer U, Hochhaus A. Liposomal encapsulated anti-cancer drugs. Anticancer Drugs 2005; 16:691-707.
17. Working PK, Newman MS, Sullivan T, Yarrington J. Reduction of the cardiotoxicity of doxorubicin in rabbits and dogs by encapsulation in long-circulating, pegylated liposomes. J Pharmacol Exp Ther 1999; 289:1128-1133.
18. Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Cohen R, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994; 54:987-993.
19. Chang J, Rao NV, Markewitz BA, Hoidal JR, Michael JR. Nitric oxide donor prevents hydrogen peroxide-mediated endothelial cell injury. Am J Physiol 1996; 270:L931-L940.
20. Monastyrskaya E, Folarin N, Malyshev I, Green C, Andreeva L. Application of the nitric oxide donor SNAP to cardiomyocytes in culture provides protection against oxidative stress. Nitric Oxide 2002; 7:127-131.
21. Hida A, Kawakami A, Miyashita T, Yamasaki S, Nakashima K, Tanaka F, et al. Nitric oxide acts on the mitochondria and protects human endothelial cells from apoptosis. J Lab Clin Med 2004; 144:148-155.
22. Maejima Y, Adachi S, Morikawa K, Ito H, Isobe M. Nitric oxide inhibits myocardial apoptosis by preventing caspase-3 activity via S-nitrosylation. J Mol Cell Cardiol 2005; 38:163-174.
23. Cole MP, Chaiswing L, Oberley TD, Edelmann SE, Piascik MT, Lin SM, et al. The protective roles of nitric oxide and superoxide dismutase in adriamycin-induced cardiotoxicity. Cardiovasc Res 2006; 69:186-197.
24. Chaiswing L, Cole MP, Ittarat W, Szweda LI, St Clair DK, Oberley TD. Manganese superoxide dismutase and inducible nitric oxide synthase modify early oxidative events in acute adriamycin-induced mitochondrial toxicity. Mol Cancer Ther 2005; 4:1056-1064.
25. Evig CB, Kelley EE, Weydert CJ, Chu Y, Buettner GR, Burns CP. Endogenous production and exogenous exposure to nitric oxide augment doxorubicin cytotoxicity for breast cancer cells but not cardiac myoblasts. Nitric Oxide 2004; 10:119-129.
26. Wink DA, Cook JA, Christodoulou D, Krishna MC, Pacelli R, Kim S, et al. Nitric oxide and some nitric oxide donor compounds enhance the cytotoxicity of cisplatin. Nitric Oxide 1997; 1:88-94.
27. Cook JA, Krishna MC, Pacelli R, DeGraff W, Liebmann J, Mitchell JB, et al. Nitric oxide enhancement of melphalan-induced cytotoxicity. Br J Cancer 1997; 76:325-334.
28. Adams DJ, Levesque MC, Weinberg JB, Smith KL, Flowers JL, Moore J, et al. Nitric oxide enhancement of fludarabine cytotoxicity for B-CLL lymphocytes. Leukemia 2001; 15:1852-1859.
29. Lavagna C, Del Soldato P, Burgaud JL, Rampal P. Nitric oxide-releasing non steroidal anti-inflammatory drugs: a new generation of anti-tumoral molecules. Curr Cancer Drug Targets 2003; 3:407-426.
30. Yeh RK, Chen J, Williams JL, Baluch M, Hundley TR, Rosenbaum RE, et al. NO-donating nonsteroidal antiinflammatory drugs (NSAIDs) inhibit colon cancer cell growth more potently than traditional NSAIDs: a general pharmacological property? Biochem Pharmacol 2004; 67:2197-2205.
31. Santucci L, Mencarelli A, Renga B, Pasut G, Veronese F, Zacheo A, Germani A, et al. Nitric oxide modulates proapoptotic and antiapoptotic properties of chemotherapy agents: the case of NO-pegylated epirubicin. FASEB J 2006; 20:765-767.
32. Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies. Clin Pharmacokinet 2003; 42:419-436.
33. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004; 56:185-229.
34. Kim YM, Talanian RV, Billiar TR. Nitric oxide inhibits apoptosis by preventing increases in caspase-3-like activity via two distinct mechanisms. J Biol Chem 1997; 272:31138-31148.
35. Li J, Billiar TR, Talanian RV, Kim YM. Nitric oxide reversibly inhibits seven members of the caspase family via S-nitrosylation. Biochem Biophys Res Commun 1997; 240:419-424.
36. Kim YM, Kim TH, Chung HT, Talanian RV, Yin XM, Billiar TR. Nitric oxide prevents tumor necrosis factor alpha-induced rat hepatocyte apoptosis by the interruption of mitochondrial apoptotic signaling through S-nitrosylation of caspase-8. Hepatology 2000; 32:770-778.
37. Mital S, Barbone A, Addonizio LJ, Quaegebeur JM, Mosca RJ, Oz MC, et al. Endogenous endothelium-derived nitric oxide inhibits myocardial caspase activity: implications for treatment of end-stage heart failure. J Heart Lung Transplant 2002; 21:576-585.
38. Fiorucci S, Mencarelli A, Palazzetti B, Del Soldato P, Morelli A, Ignarro LJ. An NO derivative of ursodeoxycholic acid protects against Fas-mediated liver injury by inhibiting caspase activity. Proc Natl Acad Sci U S A 2001; 98:2652-2657.
39. h1-like cytokines. Gastroenterology 2000; 118:404-421.
40. 2+-ATPase in myocardial and skeletal muscle sarcoplasmic reticulum: physiological implications. Med Sci Monit 2000; 6:480-485.
41. Beltran B, Mathur A, Duchen MR, Erusalimsky JD, Moncada S. The effect of nitric oxide on cell respiration: a key to understanding its role in cell survival or death. Proc Natl Acad Sci U S A 2000; 97:14602-14607.
42. Brune B. Nitric oxide: NO apoptosis or turning it ON? Cell Death Differ 2003; 10:864-869.
43. Ambrosiani G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997; 3:917-921.
44. Wang Z, Fukuda S, Pelus LM. Survivin regulates the p53 tumor suppressor gene family. Oncogene 2004; 23:8146-8153.
45. Chao JI, Kuo PC, Hsu TS. Down-regulation of survivin in nitric oxide-induced cell growth inhibition and apoptosis of the human lung carcinoma cells. J Biol Chem 2004; 279:20267-20276.
46. Hittelet A, Legendre H, Nagy N, Bronckart Y, Pector JC, Salmon I, et al. Upregulation of galectins-1 and -3 in human colon cancer and their role in regulating cell migration. Int J Cancer 2003; 103:370-379.
47. Rabinovich GA. Galectin-1 as a potential cancer target. Br J Cancer 2005; 92:1188-1192.